Kian

Kian Therapeutics is a biotechnology company focused on developing next-generation therapies for RAS-driven cancers, which represent some of the most challenging and prevalent mutations in oncology. The company utilizes a proprietary platform to design highly selective inhibitors that target various isoforms and mutant states of the RAS protein, including KRAS, HRAS, and NRAS. By addressing the structural complexities of the RAS binding pocket, Kian aims to overcome the limitations of first-generation KRAS inhibitors and provide more durable clinical responses. Their pipeline is currently in the pre-clinical stage, with a primary focus on indications such as pancreatic, colorectal, and non-small cell lung cancers.